Does metabolic syndrome influence psoriasis?

European Review for Medical and Pharmacological Sciences

Volumn 12, Issue 5, 2008, Pages 339-341

  Saraceno, Rosita ^a   Ruzzetti, M ^a   De Martino, M U ^b   Di Renzo, L ^a   Cianci, R ^c   De Lorenzo, A ^d   Chimenti, S ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c National Institute for Mediterranean Diet and Nutrigenomic   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

Metabolic syndrome; Multidisciplinary approach; Psoriasis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CHOLESTEROL; GLIBENCLAMIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; RAMIPRIL; ROSIGLITAZONE; TRIACYLGLYCEROL;

AGED; ARTICLE; BODY MASS; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; COMORBIDITY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DRUG MECHANISM; DYSLIPIDEMIA; ERYTHEMA; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOCHOLESTEROLEMIA; HYPOGLYCEMIA; LIPID ANALYSIS; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL ASSESSMENT; OUTCOME ASSESSMENT; PATIENT MONITORING; PSORIASIS; SCORING SYSTEM; SKIN DEFECT; TREATMENT DURATION; WEIGHT REDUCTION;

AGED; ANTHROPOMETRY; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC SYNDROME X; PSORIASIS; THIAZOLIDINEDIONES;

EID: 56849123206     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. GISONDI P, TESSARI G, CONTI A, PIASERICO S, SCHIANCHI S, PESERICO A, GIANNETTI A, GIROLOMONI G. Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.
2. ECKEL RH, GRUNDY SM, ZIMMET PZ. The metabolic syndrome. Lancet 2005; 365:1415-1428.
3. LAKKA HM, LAAKSONEN DE, LAKKA TA, NISKANEN LK, KUMPUSALO E, TUOMILEHTO J, SALONEN JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288:2709-2716.
4. TILG H, MOSCHEN AR. Adipocytokines: Mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-783.
5. SOMMER DM, JENISCH S, SUCHAN M, CHRISTOPHERS E, WEICHENTHAL M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-328.
6. BHAGAVATHULA N, NERUSU KC, LAL A, ELLIS CN, CHITTIBOYINA A, AVERY MA, HO CI, BENSON SC, PERSHADSINGH HA, KURTZ TW, VARANI J. Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes. J Invest Dermatol 2004; 122: 130-139.
7. PERSHADSINGH HA, BENSON SC, ELLIS CN. Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient. Skinmed 2005; 4: 386-390.
8. ELLIS CN, BARKER JN, HAIG AE, PARKER CA, DALY S, JAYAWARDENE DA; AVANDIA PSORIASIS STUDY GROUP. Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone. Am J Clin Dermatol 2007; 8: 93-102.
9. COHEN AD, SHERF M, VIDAVSKY L, VARDY DA, SHAPIRO J, MEYEROVITCH J. Association between psoriasis and the metabolic syndrome. Dermatology 2008; 216: 152-155.
10. LOWES MA, BOWCOCK AM, KRUEGER JG. Pathogenesis and therapy of psoriasis. Nature 2007; 22: 866-873.